1. J. Y. Vanderhoek, R. W. Bryant, and J. M. Bailey,Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. J. Biol. Chem.255, 10064–10066 (1980).
2. S. M. Coutts, A. Khandwala, R. van Inwegen, U. Chakraborty, J. Musser, J. Bruens, N. Jariwala, V. Dally-Meade, R. Ingram, T. Pruss, H. Jones, E. Neiss, and I. Weinryb,Arymethyl phenyl ethers. A new class of specific inhibitors of 5-lipoxygenase. InProstaglandins, Leukotrienes and Lipoxins. Biochemistry, Mechanism of Action, and Clinical Applications. (Ed. J. M. Bailey) pp. 627–637. Plenum Press, New York, 1985.
3. R. Müller-Peddinghaus, R. Fruchtmann, H.-J., Ahr, B. Beckermann, K. Bühner, B. Fugmann, B. Junge, M. Matzke, C. Kohlsdorfer, S. Raddatz, P. Theisen-Popp and K.-H. Mohrs,BAY X 1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. J. Lipid Mediators6, 245–248 (1993).
4. R. Müller-Peddinghaus, C. Kohlsdorfer, P. Theisen-Popp, R. Fruchtmann, E. Perzborn, B. Beckerman, K. Bühner, H.-J. Ahr and K.-H. Mohrs,BAY X 1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J. Pharmacol. Exp. Therap.,267, 51–57 (1993).
5. I. Gorenne, C. Labat, J. P. Gascard, X. Norel, R. Müller-Peddinghaus, K. H. Mohrs, W. A. Taylor, P. J. Gardiner, and C. Brink,(R)-2-[4-(quinolin-2-yl-methoxy) phenyl]-2-cyclopentyl] acetic acid (BAY X 1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J. Pharmacol. Exp. Therap.,268, 868–872 (1993).